BTIG raises BrightSpring Health stock price target on strong results

BrightSpring Health Services reported Q1 2026 EPS of $0.39, beating the $0.16 estimate, on revenue of $3.61 billion. BTIG raised its price target to $65 from $55 while keeping a Buy rating, citing 36% year-over-year specialty and infusion revenue growth, 48% growth in EBITDA per prescription, and expected $30 million of 2026 EBITDA from the Amedisys/LHC integration. The company also completed the divestiture of its Community Living business for about $811 million in pre-tax cash proceeds.

Analysis

The market is starting to price BrightSpring less as a turnaround and more as a quality compounder, but the real story is margin mix, not headline growth. Specialty/infusion and limited-distribution drugs typically carry better economics and stickier payer relationships than the broader pharmacy book, so the mix shift can keep expanding EBITDA even if prescription counts stay soft. That makes the business look more resilient than a pure volume story and helps explain why the stock has re-rated so aggressively.

The divestiture proceeds are an underappreciated second-order catalyst: the balance-sheet reset gives management flexibility to delever, repurchase stock, or fund tuck-in assets that deepen distribution exclusivity. If they prioritize debt reduction first, the equity could get another de-risking leg as the market assigns a lower earnings multiple to a cleaner capital structure. The Amedisys/LHC integration benefit also matters because it suggests the company is starting to monetize scale synergies in provider services, which can support estimates for multiple quarters rather than one quarter.

The main risk is that expectations are now high enough that normal execution can disappoint. At this valuation, any slowdown in drug onboarding, payer pressure, or integration slippage will likely compress the multiple before it impacts the top line, so the stock is increasingly sensitive to forward guidance rather than reported results. The better short thesis is not that the business deteriorates, but that the next few quarters fail to justify a premium multiple after a 150%+ run.

Consensus may be underestimating how much of the upside has already been pulled forward by estimate revisions and the post-earnings squeeze. The more interesting contrarian angle is that the cleanest risk/reward may now be in hedged expression rather than outright long exposure: the company can keep executing while still giving back part of the move if growth normalizes from exceptional to merely good. That argues for using strength to monetize upside or rotate into a relative-value structure instead of chasing the stock unhedged.

Key Decisions for Investors

• Trim outright BTSG longs into strength over the next 1-2 weeks; the stock has re-rated ahead of the integration and capital-allocation story, so upside from here is more execution-dependent than surprise-dependent.
• If looking to stay exposed, buy BTSG Jan-2027 calls financed by selling higher-strike calls or put spreads; this keeps participation in another 10-20% rerating while limiting downside if the multiple compresses.
• Pair trade: long BTSG / short a lower-growth healthcare services basket over 1-3 months, but keep the hedge beta-neutral; the relative story is stronger than the index-level story if margin expansion persists.
• Watch for capital return or debt paydown announcements over the next 1-2 quarters; a materially faster deleveraging path would justify adding back risk, while any M&A drift would be a warning sign.
• For a tactical short, consider a small BTSG put spread dated 3-6 months out only if the stock trades materially above the new target range; the short is a valuation-and-expectations trade, not a fundamental collapse thesis.